RIGL

Rigel Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-03

Figures on this page computed 2026-11-08 12:56 UTC

Last close

51.29USD

Market data, 2026-11-04

RIGL: weekly closes from 42.58 on 2026-08-14 to 51.29 on 2026-11-04, a move of +20.5%. Prices in USD.

Weekly closes, 2026-08-14 to 2026-11-04

Over that span: +20.5%

Except where said otherwise: 10-K for 2025, filed 2026-03-03

1.9xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-03
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
The filing itself
n/mNet marginnet income exceeds revenue
Net income exceeds revenue.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

2.68x

-116.91x

n/a

1.16x

2.04x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-03

Sales2.68x
Its own average over 10 years, 109.7M.
Profit-116.91x
Its own average over 10 years, -3.1M.
Free cash flown/a
Its own average over 7 years, -54.2M.
Debt1.16x
Its own average over 7 years, 46.2M.
Price2.04x
Its own average over 11 years, 25. Market data, 2026-11-04

Profit is furthest from its own average, at -116.91 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2016-12-31	100.0	n/a
2017-12-31	22.0	n/a
2018-12-31	218.4	n/a
2019-12-31	290.9	100.0
2020-12-31	532.9	100.8
2021-12-31	732.2	101.8
2022-12-31	589.9	101.8
2023-12-31	573.4	103.9
2024-12-31	879.5	105.7
2025-12-31	1,443.8	112.5

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001034842-26-000015
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001034842-26-000015
Reported in: USD

The filing itself

Figures behind the shape

Growth

22.1%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate22.1%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income1999.1%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

93.8%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
The filing itself
Return on equity93.8%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
The filing itself
Return on assets71.5%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
The filing itself

Margins

93.3%

wider is higher, placed against 3,598 companies as of 2026-11-07

Gross margin93.3%
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
Operating margin42.6%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
Net marginn/mnet income exceeds revenue
Net income exceeds revenue.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
Free cash flow marginn/a
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself

Price

1.9x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earnings1.9x
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-03
The filing itself
Price to book1.9x10-Q for 2025, filed 2026-08-04
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001034842-26-000052
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-04
- computed
- 10-K for 2025, filed 2026-03-03
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
- 10-K for 2025, filed 2026-03-03
The filing itself
Price to sales ratio2.5x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself

Safety

2.42

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equityn/a
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
The filing itself
Current ratio2.4210-Q for 2025, filed 2026-08-04
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001034842-26-000052
Reported in
USD
- 10-Q for 2025, filed 2026-08-04
- 10-Q for 2025, filed 2026-08-04
The filing itself
Interest coverage17.1x
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
Altman Z-Score2.59
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-03-03
- Computed from the 10-K for 2025, filed 2026-03-03
- Computed from the 10-K for 2025, filed 2026-03-03
- Computed from the 10-K for 2025, filed 2026-03-03
- Computed from the 10-K for 2025, filed 2026-03-03

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- Computed from the 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.